Concepedia

Author

Qingyan Bo

Roche (China)

Also Known As

Q. Bo, Qingyan Bo

17

Publications

285

Citations

9

H-Index

9

Concepts

All Affiliations

Roche (China)Roche (Switzerland)Beijing Friendship HospitalSouthern Medical UniversityHenan Provincial People's Hospital
QB

About

Qingyan Bo is an author at Roche (China) specializing in viral hepatitis, hepatitis, and hepatitis b.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

101

2

Viral Hepatitis

3

3

101

3

Hepatology

2

2

81

4

Immunology

2

2

44

5

Pharmacology

1

1

57

Qingyan Bo

×

9

Publications

241

Citations

9

H-Index

YearCitations

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

Man‐Fung Yuen, Xue Zhou, Edward Gane,

˜The œLancet. Gastroenterology & hepatology

2021

57

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

Jinlin Hou, Wenhong Zhang, Qing Xie,

New England Journal of Medicine

2024

55

What drives the dynamics of HBV RNA during treatment?

António Gonçalves, Annabelle Lemenuel‐Diot, Valérie Cosson,

Journal of Viral Hepatitis

2020

26

RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated

Edward Gane, A. Liu, MF Yuen,

Journal of Hepatology

2018

24

A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants

Sheng Feng, Edward Gane, Christian Schwabe,

Antimicrobial Agents and Chemotherapy

2020

22

FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients

Edward Gane, Man‐Fung Yuen, Qingyan Bo,

Journal of Hepatology

2019

20

Nationwide survey of specialist knowledge on current standard of care (Peg‐IFN/RBV) and barriers of care in chronic hepatitis C patients in China

Lai Wei, Jie Li, Xizhong Yang,

Journal of Gastroenterology and Hepatology

2016

14

Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B

Sheng Feng, Qingyan Bo, H. Coleman,

The Journal of Clinical Pharmacology

2021

13

Real-World Evidence for Nucleoside/Nucleotide Analogues in a 5-Year Multicentre Study of Antiviral-Naive Chronic Hepatitis B Patients in China: 52-Week Results

Jidong Jia, Hong Tang, Qin Ning,

Antiviral Therapy

2017

10

Page 1